

Request for permission for oral testimony at Idaho
Medicaid's P&T Committee meeting on 04-15-2011

Submission # 2

The following request has been:

☐ Approved

☒ Denied

Gennrich, Jane - Medicaid

From: Eide, Tamara J. - Medicaid
Sent: Friday, March 11, 2011 3:25 PM
To: Gennrich, Jane - Medicaid
Subject: FW:
Attachments: Idaho medicaid P&TAvandia.docx

Tami Eide, Pharm.D., BCPS

Medicaid Pharmacy Program Supervisor/Manager
Idaho Department of Health and Welfare
eidet@dhw.idaho.gov
3232 Elder St.
Boise, ID 83705
208-364-1829
800-327-5541 fax

From: Linda Dawson [<mailto:linda.j.dawson@gsk.com>]
Sent: Friday, March 11, 2011 3:23 PM
To: Eide, Tamara J. - Medicaid
Subject:

Greetings,

Please see the attached request in regards to new information on *Avandia*, *Avandamet* and *Avandaryl* for your upcoming P&T committee meeting.

Regards, Linda

Linda J. Dawson, Pharm.D., MPH, CPH
Sr. Medical Information Scientist II
GlaxoSmithKline
Medical Information Department
T (919) 483-4177
Fax (919) 315-3081
email: linda.j.dawson@gsk.com
<http://www.gsk.com>

March 10, 2011

Robert Faller, RPh

fallerr@dhw.idaho.gov

Dear Idaho P&T Committee:

Based on the submission guidelines for the public comment process, I would like to request that I be allowed to present new information that has recently become available for rosiglitazone-containing products, namely *Avandia*® (rosiglitazone maleate), *Avandamet*® (rosiglitazone maleate/metformin hydrochloride) and *Avandaryl*® (rosiglitazone maleate/glimepiride) at your upcoming April 15th 2011 Idaho Medicaid P&T review meeting.

- On September 23, 2010, the FDA requested the implementation of restrictions on the use of rosiglitazone-containing products to eligible patients through a Risk Evaluation and Mitigation Strategy (REMS) program to assure safe use of the products. In addition, labeling changes were announced on February 7, 2011 in response to the FDA's review of cardiovascular event data in type 2 diabetes patients receiving rosiglitazone. I can share with the committee the information currently available about the proposed REMS program as well as the revised prescribing information for the rosiglitazone products.
- Thank you in advance for your consideration of my request.

Sincerely,

Robert R Pearson, Pharm. D.
Senior Regional Medical Scientist
GlaxoSmithKline Research and Development
North American Medical Affairs
(801) 718-3122